Current Pathobiology Reports

, Volume 6, Issue 4, pp 233–240 | Cite as

Hepatic Manifestations in Glycogen Storage Disease Type III

  • Aditi Korlimarla
  • Stephanie Austin
  • Baodong Sun
  • Priya KishnaniEmail author
Pathobiology of Orphan Diseases (S Ranganathan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pathobiology of Orphan Diseases


Purpose of Review

Glycogen storage disease type III (GSD III) is an orphan disease that mainly affects the liver, heart, and skeletal muscles. It is caused by the deficiency of glycogen debranching enzyme (GDE), resulting in accumulation of glycogen (limit dextrin) primarily in the cytoplasm. With an increase in life expectancy in patients and advances in research, long-term hepatic manifestations are being recognized. This review examines our understanding of the natural history of the hepatic manifestations of GSD III and the importance of developing definitive therapies.

Recent Findings

Animal models have shown specific trends in biochemical and histological features such as changes in liver enzymes and progressive hepatic fibrosis, with increasing age. In our clinical experience, patients with GSD III show similar trends.


Our review highlights (a) hepatic manifestations in GSD III, (b) the natural history, (c) existing animal models, and (d) current research on therapeutic approaches.


Glycogen storage disease III AGL gene variants Glycogen debranching enzyme deficiency Hepatic manifestations Liver fibrosis 



We thank Dr. Carine Halaby for editing a draft of the manuscript and for providing help with literature searches in GSD III.

Compliance with Ethical Standards

Conflict of Interest

P.S.K. reports receiving research grant from Genzyme. B.S. reports receiving research grant from Roivant Sciences. P.S.K. and B.S. are listed as inventors on a Duke University patent for the use of rhGAA in the treatment of GSD III and other GSDs excluding GSD II. To date, neither Duke University nor the inventors has received any money from the commercialization of rights associated with this patent. The other authors (A.K. and S.A.) declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Illingworth B, Cori GT, Cori CF. Amylo-1, 6-glucosidase in muscle tissue in generalized glycogen storage disease. J Biol Chem. 1956;218(1):123–9.PubMedGoogle Scholar
  2. 2.
    Bao Y, Dawson JTL, Chen Y-T. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5′ flanking region. Genomics. 1996;38(2):155–65.PubMedGoogle Scholar
  3. 3.
    Ding J-H, de Barsy T, Brown BI, Coleman RA, Chen YT. Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III. J Pediatr. 1990;116(1):95–100.PubMedGoogle Scholar
  4. 4.
    Coleman RA, Winter HS, Wolf B, Chen YT. Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis. 1992;15(6):869–81.PubMedGoogle Scholar
  5. 5.
    Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA, et al. Glycogen storage disease in adults. Ann Intern Med. 1994;120(3):218–26.PubMedGoogle Scholar
  6. 6.
    Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12(7):446–63.PubMedGoogle Scholar
  7. 7.
    Goldstein JL, Austin SL, Boyette K, Kanaly A, Veerapandiyan A, Rehder C, et al. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. Genetics In Medicine. 2010;12:424–30.PubMedGoogle Scholar
  8. 8.
    Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest. 1996;98(2):352–7.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Shen JJ, Chen YT. Molecular characterization of glycogen storage disease type III. Curr Mol Med. 2002;2(2):167–75.PubMedGoogle Scholar
  10. 10.
    Lu C, Qiu Z, Sun M, Wang W, Wei M, Zhang X. Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations. J Hum Genet. 2016;61(7):641–5.PubMedGoogle Scholar
  11. 11.
    •• Brooks ED, Yi H, Austin SL, Thurberg BL, Young SP, Fyfe JC, et al. Natural progression of canine glycogen storage disease type IIIa. Comp Med. 2016;66(1):41–51. This is a long-term folow up study which demonstrates trends in biomarkers (ALT, AST, urinary Glc4) in GSD IIIa canine models. When implemented in patients with GSD III, levels of serum hepatic transaminases and urinary Glc4 serve as good biomarkers of disease progression. Google Scholar
  12. 12.
    •• Surkov AN, et al. Transient elastography is a noninvasive method to diagnose hepatic fibrosis stages in children with rare diseases. Medical Technologies in Medicine / Sovremennye Tehnologii v Medicine. 2016;8(3):56–62. This study highlights the use of a non-invasive imaging technique with high reproducibility which could be beneficial for monitoring liver pathology in patients with GSD III. Google Scholar
  13. 13.
    •• Singh S, Loomba R. Role of two-dimensional shear wave elastography in the assessment of chronic liver diseases. Hepatology. 2018;67(1):13–5. This study highlights the use of a non-invasive imaging technique which could be beneficial for monitoring liver pathology in patients with GSD III. Google Scholar
  14. 14.
    Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS. The electrodiagnostic characteristics of glycogen storage disease type III. Genetics In Medicine. 2010;12:440–5.PubMedGoogle Scholar
  15. 15.
    • Sentner CP, Hoogeveen IJ, Weinstein DA, Santer R, Murphy E, McKiernan PJ, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016;39:697–704. This study is The International Study on Glycogen Storage Disease (ISGSDIII). It is descriptive, retrospective, international, and multi-centric. It consists of 175 patients from 147 families with follow-up into adulthood in 91 patients. Google Scholar
  16. 16.
    Hershkovitz E, Forschner I, Mandel H, Spiegel R, Lerman-Sagie T, Anikster Y, et al. Glycogen storage disease type III in Israel: presentation and long-term outcome. Pediatr Endocrinol Rev. 2014;11(3):318–23.PubMedGoogle Scholar
  17. 17.
    Franchi-Abella S, Branchereau S. Benign hepatocellular tumors in children: focal nodular hyperplasia and hepatocellular adenoma. Int J Hepatol. 2013;2013:215064.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Shimizu, J, et al, [A report on an adult case of type III glycogenosis with primary liver cancer and liver cirrhosis]. Nihon Shokakibyo Gakkai Zasshi, 1982. 79(12): p. 2328–32.Google Scholar
  19. 19.
    Haagsma EB, Smit GP, Niezen-Koning KE, Gouw AS, Meerman L, Slooff MJ, et al. Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The liver transplant group. Hepatology. 1997;25(3):537–40.PubMedGoogle Scholar
  20. 20.
    Siciliano M, de Candia E, Ballarin S, Vecchio FM, Servidei S, Annese R, et al. Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. J Clin Gastroenterol. 2000;31(1):80–2.PubMedGoogle Scholar
  21. 21.
    Cosme, A, et al, [Type III glycogen storage disease associated with hepatocellular carcinoma]. Gastroenterol Hepatol, 2005. 28(10): p. 622–5.Google Scholar
  22. 22.
    Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, et al. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol. 2007;46(3):492–8.PubMedGoogle Scholar
  23. 23.
    Oterdoom LH, Verweij KE, Biermann K, Langeveld M, van Buuren H. Hepatocellular adenomas and carcinoma in asymptomatic, non-cirrhotic type III glycogen storage disease. J Gastrointestin Liver Dis. 2015;24(4):515–8.PubMedGoogle Scholar
  24. 24.
    Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant. 2008;12(2):137–45.PubMedGoogle Scholar
  25. 25.
    Iyer SG, Chen CL, Wang CC, Wang SH, Concejero AM, Liu YW, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl. 2007;13(6):848–52.PubMedGoogle Scholar
  26. 26.
    Superina RA, Pearl RH, Roberts EA, Phillips MJ, Graham N, Greig PD, et al. Liver transplantation in children: the initial Toronto experience. J Pediatr Surg. 1989;24(10):1013–9.PubMedGoogle Scholar
  27. 27.
    Matern D, Starzl TE, Arnaout W, Barnard J, Bynon JS, Dhawan A, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr. 1999;158(Suppl 2):S43–8.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Liu PP, de Villa VH, Chen YS, Wang CC, Wang SH, Chiang YC, et al. Outcome of living donor liver transplantation for glycogen storage disease. Transplant Proc. 2003;35(1):366–8.PubMedGoogle Scholar
  29. 29.
    Shirasawa Y, et al. Liver transplantation-associated hypercalcemia followed by acute renal dysfunction. Intern Med. 2004;43(9):802–6.PubMedGoogle Scholar
  30. 30.
    Lucchiari S, Santoro D, Pagliarani S, Comi GP. Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. Acta Myologica. 2007;26(1):72–4.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Ustundag Y, et al. The utility of AST/ALT ratio as a non-invasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis. Nephrol Dial Transplant. 2000;15(10):1716–7.PubMedGoogle Scholar
  32. 32.
    Ugorski M, Seder A, Lundblad A, Zopf D. Studies on the metabolic origin of a glucose-containing tetrasaccharide in human urine. J Exp Pathol. 1983;1(1):27–38.PubMedGoogle Scholar
  33. 33.
    Walker GJ, Whelan WJ. The mechanism of carbohydrase action. 7. Stages in the salivary α-amylolysis of amylose, amylopectin and glycogen. Biochem J. 1960;76(2):257–63.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Kumlien J, Chester MA, Lindberg BS, Pizzo P, Zopf D, Lundblad A. Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen. Clin Chim Acta. 1988;176(1):39–48.PubMedGoogle Scholar
  35. 35.
    Winchester B, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab. 2008;93(3):275–81.PubMedGoogle Scholar
  36. 36.
    Young SP, Stevens RD, An Y, Chen YT, Millington DS. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. Anal Biochem. 2003;316(2):175–80.PubMedGoogle Scholar
  37. 37.
    Manwaring V, Prunty H, Bainbridge K, Burke D, Finnegan N, Franses R, et al. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inherit Metab Dis. 2012;35(2):311–6.PubMedGoogle Scholar
  38. 38.
    An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corzo D, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab. 2005;85(4):247–54.PubMedGoogle Scholar
  39. 39.
    • Herbert, M., Pendyal S., Rairikar M., Halaby C., Benjamin R.W., Kishnani P.S., Role of continuous glucose monitoring in the management of glycogen storage disorders. J Inherit Metab Dis, 2018. This study highlights the use of CGMS which can detect asymptomatic hypoglycemia and prevent complications in patients with GSD III.Google Scholar
  40. 40.
    Li XH, Gong QM, Ling Y, Huang C, Yu DM, Gu LL, et al. Inherent lipid metabolic dysfunction in glycogen storage disease IIIa. Biochem Biophys Res Commun. 2014;455(1–2):90–7.PubMedGoogle Scholar
  41. 41.
    Choy PC, Siow YL, Mymin D, O K. Lipids and atherosclerosis. Biochem Cell Biol. 2004;82(1):212–24.PubMedGoogle Scholar
  42. 42.
    Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–65.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Liu KM, Wu JY, Chen YT. Mouse model of glycogen storage disease type III. Mol Genet Metab. 2014;111(4):467–76.PubMedGoogle Scholar
  44. 44.
    Pagliarani S, Lucchiari S, Ulzi G, Violano R, Ripolone M, Bordoni A, et al. Glycogen storage disease type III: a novel Agl knockout mouse model. Biochim Biophys Acta. 2014;1842(11):2318–28.PubMedGoogle Scholar
  45. 45.
    Yi H, Thurberg BL, Curtis S, Austin S, Fyfe J, Koeberl DD, et al. Characterization of a canine model of glycogen storage disease type IIIa. Dis Model Mech. 2012;5(6):804–11.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Yi H, Brooks ED, Thurberg BL, Fyfe JC, Kishnani PS, Sun B. Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med (Berl). 2014;92(6):641–50.Google Scholar
  47. 47.
    Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109.PubMedGoogle Scholar
  48. 48.
    Sun B, Fredrickson K, Austin S, Tolun AA, Thurberg BL, Kraus WE, et al. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III. Mol Genet Metab. 2013;108(2):145–7.PubMedGoogle Scholar
  49. 49.
    Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18(1):80–6.PubMedGoogle Scholar
  50. 50.
    •• Vidal P, Pagliarani S, Colella P, Costa Verdera H, Jauze L, Gjorgjieva M, et al. Rescue of GSDIII phenotype with gene transfer requires liver- and muscle-targeted GDE expression. Mol Ther. 2018;26(3):890–901. This study hihglights the use of a dual overlapping AAV system in gene therapy which could be a promising definitive therapy in patients with GSD III. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Aditi Korlimarla
    • 1
  • Stephanie Austin
    • 1
  • Baodong Sun
    • 1
  • Priya Kishnani
    • 1
    Email author
  1. 1.Division of Medical Genetics, Department of PediatricsDuke University Medical CenterDurhamUSA

Personalised recommendations